The FDA has approved Ozempic to help lower chronic kidney disease-related risks in people with type 2 diabetes. The findings of a recent clinica trial, funded by drugmaker Novo Nordisk, indicate ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, end-stage kidney disease and cardiovascular disease-caused death for patients ...

Should you consider Ozempic to reduce your stroke risk? Before starting Ozempic or another GLP-1 to ward off a stroke, you should have a conversation with your doctor or healthcare professional.

The approval was based on data from a late-stage study, which showed that Ozempic helped cut the risk of death from chronic kidney disease and major cardiac events by 24%, the company said.

Ozempic is now FDA-approved to reduce chronic kidney disease risks in diabetes patients. A Phase 3 trial showed Ozempic reduced kidney disease worsening by 24% and heart-related deaths by 5%.

The approval was based on data from a late-stage study, which showed that Ozempic helped cut the risk of death from chronic kidney disease and major cardiac events by 24%, the company said.

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, end-stage kidney disease and cardiovascular disease-caused death for patients ...

Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease, drugmaker Novo Nordisk said Tuesday.

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, end-stage kidney disease and cardiovascular disease-caused death for patients ...

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.